medigraphic.com
ISSN 1527-3172 (Electronic)

2017, Number 1

<< Back Next >>

MEDICC Review 2017; 19 (1)

Antituberculosis drug resistance in pulmonary isolates of Mycobacterium tuberculosis, Cuba 2012–2014

Lemus MD, Echemendía FM, Díaz RR, Llanes CMJ, Suárez ÁL, Marrero FA

Language: English
References: 27
Page: 10-15
PDF size: 341.04 Kb.


ABSTRACT

Introduction Systematic surveillance of antituberculosis drug resistance allows identification of multidrug-resistant and extensively drug-resistant isolates of Mycobacterium tuberculosis. Surveillance studies of antituberculosis drug resistance systematically conducted in Cuba for over 15 years have revealed low circulation of multidrug-resistant tuberculosis, under 1% in new cases.
Objective Characterize antituberculosis drug resistance in isolates of M. tuberculosis recovered from patients with pulmonary tuberculosis in Cuba in 2012–2014.
Methods The nitrate reductase assay was used to test 997 isolates of M. tuberculosis for sensitivity to isoniazid and rifampicin. Isolates identified as multidrug resistant were tested for sensitivity to isoniazid, rifampicin, streptomycin, ethambutol, ofloxacin, amikacin, kanamycin and capreomycin by the proportion method, as well as genetic resistance mutations in rpoB, katG, inhA, gyrA, rrs and embB genes, using GenoType MTBDRplus and MTBDRs/ commercial kits.
Results Some 95.6% of isolates from new cases and 89.6% of isolates from previously treated patients were sensitive to isoniazid and rifampicin. Multidrug resistance was found in 0.8% of new and 5.2% of previously treated patients, a statistically significant difference. One extensively drug-resistant isolate was detected among previously treated cases. All isolates examined with the molecular method had mutations in the rpoB gene, which is associated with resistance to rifampicin; only seven showed mutations in the katG gene and one in the inhA gene associated with isoniazid resistance. In one isolate, we found mutations in both gyrA and rrs genes, which are associated with resistance to fluoroquinolones and second-line injectable drugs and therefore, extensive resistance.
Conclusions Results corroborate the low frequency of multidrug-resistant and extensively resistant M. tuberculosis strains in Cuba and highlight the need for continuous improvement of surveillance of antituberculosis drug resistance in Cuba.


REFERENCES

  1. World Health Organization. Global tuberculosis control: WHO report 2014. Geneva: World Health Organization; 2014. 171 p.

  2. World Health Organization. Global tuberculosis control: WHO report 2015. Geneva: World Health Organization; 2015. 192 p.

  3. Caminero JA, editor. Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis. Paris: International Union Against Tuberculosis and Lung Disease; 2013. 240 p.

  4. World Health Organization. Directrices para la vigilancia de la farmacorresistencia en la tuberculosis. 5th ed. Geneva: World Health Organization; 2016. 76 p. Spanish.

  5. Pan American Health Organization. La tuberculosis en la Región de las Américas. Informe Regional 2011. Epidemiología, control y fi nanciamiento. Washington, D.C.: Pan American Health Organization; 2011. 53 p. Spanish.

  6. Pan American Health Organization. La tuberculosis en la Región de las Américas. Informe regional 2013. Epidemiología, control y fi nanciamiento. Washington, D.C.: Pan American Health Organization; 2014. Spanish.

  7. Montoro E, Lemus D, Echemendía M, Díaz R, Mederos L, Martínez MR, et al. Vigilancia de la resistencia a los fármacos antituberculosos en Cuba, 2000–2009. Rev Panam Salud Pública. 2011;30(6):615–8. Spanish.

  8. Lemus D, Echemendía M, Díaz R, Llop A, Llanes MJ. Vigilancia de la resistencia a los medicamentos antituberculosos en Cuba, 2010–2011. Biomédica. 2014 Apr;34 Suppl1:108–13. Spanish.

  9. Ministry of Public Health (CU). Programa Nacional y Normas de Procedimiento para la Prevención y Control de la Tuberculosis. Havana: Ministry of Public Health (CU); 2013. Spanish.

  10. Palomino JC. Challenges associated with diagnostics, drug resistance and pathogenesis of Mycobacterium tuberculosis. In: Singh SK, editor. Human Emerging and Re-emerging Infections: Bacterial and Mycotic Infections. 1st ed. New York: John Wiley & Sons; 2016. Chapter 45. Vol. 2.

  11. Alcaide F, Esteban J, González-Martín J, Palacios JJ. Métodos de determinación de sensibilidad a los antimicrobianos en micobacterias. Enferm Infecc Microbiol Clin [Internet]. 2016 May [cited 2016 Jul 24]. Available from: http://dx.doi .org/10.1016/j.emc.2016.04.008. Spanish.

  12. Gaz MA, Islam MR, Kibria MG, Mahmud Z. General and advanced diagnostic tools to detect Mycobacterium tuberculosis and their drug susceptibility: a review. Eur J Clin Microbiol Infect Dis. 2015 May;34(5):851–61.

  13. World Health Organization. Noncommercial culture and drug-susceptibility testing methods for screening patients at risk for multidrug-resistant tuberculosis. Geneva: World Health Organization; 2011. 18 p.

  14. Angeby KA, Klintz L, Hoffner SE. Rapid and inexpensive drug susceptibility testing of Mycobacterium tuberculosis with a nitrate reductase assay. J Clin Microbiol [Internet]. 2002 Feb [cited 2016 Mar 4];40(2):553–5. Available from: http:// dx.doi:10.1128/JCM.40.2.553-555.2002

  15. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, Mitchison DA, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programs. Bull World Health Organ. 1969;41(1):21–43.

  16. World Health Organization. Policy guidance on drug-susceptibility testing of second-line antituberculosis drugs. Geneva: World Health Organization; 2008. 20 p.

  17. Hain Lifescience [Internet]. Nehren (DE): Hain Lifescience GmbH; c2016. Products. Genotype® MTBDRplus product insert, VER 2.0 – Your test system for a fast and reliable way to detect MDR-TB; [cited 2016 Apr 24]; [about 1 screen]. Available from: http://www.hain-lifescience.de/ en/products/microbiology/mycobacteria/tuber culosis/genotype-mtbdrplus.html

  18. Hain Lifescience [Internet]. Nehren (DE): Hain Lifescience GmbH; c2016. Products. Genotype® MTBDRs/ VER 1.0 and VER 2.0 – Your important assistance for detection of XDR-TB; [cited 2016 Apr 24]; [about 1 screen]. Available from: http:// www.hain-lifescience.de/en/products/microbio logy/mycobacteria/tuberculosis/genotype-mtb drsl.html

  19. Lemus D, Montoro E, Echemendía M, Martin A, Portaels F, Palomino JC. Nitrate reductase assay for detection of drug resistance in Mycobacterium tuberculosis: simple and inexpensive method for low resources laboratories. J Med Microbiol. 2006 Jul;55(Pt 7):861–3.

  20. Lemus Molina D, Álvarez Echaide Y, Echemendía Font M, Vander Stuyf P, Palomino JC, Martin A. Utilidad del método de la nitrato reductasa para la detección de resistencia a drogas antituberculosas de segunda línea. Rev Cub Med Trop. 2015;67(1). Spanish.

  21. González L, Sánchez R, Murcia MI. Utilidad de la prueba de la nitrato reductasa para la detección rápida de resistencia en Mycobacterium tuberculosis. Biomédica 2014;34(Suppl 1):232–8. Spanish.

  22. Domínguez J, Boettger EC, Cirillo D, Cobelens F, Eisenach KD, Gagneux S, et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESISTTB consensus statement. Int J Tuberc Lung Dis. 2016 Jan;20(1):24–42.

  23. World Health Organization. The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs. Policy guidance. WHO/HTM/TB/2016.07. Geneva: World Health Organization; 2016.

  24. Asencios L, Galarza M, Quispe N, Vásquez L, Leo E, Valencia E, et al. Prueba molecular Genotype® MTBDRplus, una alternativa para la detección rápida de tuberculosis multidrogorresistente. Rev Peru Med Exp Salud Publica. 2012 Jan–Mar;29(1):92–8. Spanish.

  25. Feliciano CS, Nascimento MM, Anselmo LM, Pocente RH, Bellissimo-Rodrigues F, Bollela VR. Role of a GenoType MTBDRplus line probe assay in early detection of multidrug-resistant tuberculosis at a Brazilian reference center. Braz J Med Biol Res. 2015 Aug;48(8):759–64.

  26. Palomino JC, Martin A. Drug resistance mechanisms in Mycobacterium tuberculosis. Antibiotics (Basel). 2014 Jul 2;3(3):317–40.

  27. Theron G, Peter J, Richardson M, Warren R, Dheda K, Steingart KR. GenoType® Mtbdrsl assay for resistance to second-line anti-tuberculosis drugs. Cochrane Database of Syst Rev. 2016 Sep 8;9:CD010705. DOI:10.1002/14651858. CD010705.pub3




2020     |     www.medigraphic.com